Search KYNB
KYNTRA BIO, INC.
Nasdaq · CIK 921299
Last close6.31
Daily change-0.19 (-2.92%)
10 Years gain-98.79%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
KYNB · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
38.6Momentum
100.0Acceleration
100.0Confidence
77.0Annual Revenue13
Quarterly Revenue44
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality2.6 / 25
Capital Efficiency20.0 / 20
Balance Sheet6.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 618.1628 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 169.7235 percentage points.
Low interest coverage · HIGHInterest coverage is -5.4974x.
Key Metrics
Revenue Growth TTM-32.99%OK
Revenue CAGR 3Y-64.23%OK
Gross Margin9.32%OK
Operating Margin-1,042.13%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.25%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $6.44M | $5.88M | -$45.90M | -$4.77M | -$4.81M | 91.37% | -712.66% | -74.72% | n/a | 4.04M |
| 2025 FY Dec 31, 2024 | $29.62M | $14.06M | -$150.42M | -$138.00M | -$138.27M | 47.47% | -507.8% | -466.78% | n/a | 4M |
| 2024 FY Dec 31, 2023 | $46.80M | $42.84M | -$322.72M | -$315.02M | -$317.54M | 91.53% | -689.53% | -678.46% | n/a | 97.3M |
| 2023 FY Dec 31, 2022 | $140.73M | $120.45M | -$301.03M | -$145.93M | -$149.67M | 85.59% | -213.9% | -106.35% | n/a | 93.58M |
| 2023 FY Dec 31, 2021 | $235.31M | $222.44M | -$288.53M | -$82.23M | -$87.42M | 94.53% | -122.62% | -37.15% | n/a | 92.35M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.69M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-349183, 0001193125-25-274241 |
| Revenue Growth TTM | -32.99% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-349183, 0001193125-25-274241 |
| Revenue CAGR 3Y | -64.23% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-108346 |
| Revenue CAGR 5Y | -48.42% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-108346 |
| Gross Profit CAGR 3Y | -63.44% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-108346 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-349183, 0001193125-25-274241 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 9.32% | Gross Profit / Revenue | OK | 0001193125-26-349183, 0001193125-25-274241 |
| Operating Margin | -1,042.13% | Operating Income / Revenue | OK | 0001193125-26-349183, 0001193125-25-274241 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-349183 |
| Interest Coverage | -5.5x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 2.69x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.16 | Revenue / Diluted Shares | OK | 0001193125-26-349183, 0001193125-25-274241 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |